MODIFICATION
68 -- GPCR-focused small molecule libraries
- Notice Date
- 8/22/2018
- Notice Type
- Modification/Amendment
- NAICS
- 325998
— All Other Miscellaneous Chemical Product and Preparation Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211, MSC 9559, Bethesda, Maryland, 20892-9559, United States
- ZIP Code
- 20892-9559
- Solicitation Number
- NIHDA201800457
- Archive Date
- 9/19/2018
- Point of Contact
- Hunter A Tjugum, Phone: 3018275304
- E-Mail Address
-
hunter.tjugum@nih.gov
(hunter.tjugum@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The Purpose of Amendment 1 is to extend the due date for accepting quotations from August 27, 2018 to September 4, 2018. All ohter terms and provisions remain unchanged. (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is NIHDA201800457 and the solicitation is issued as a Request for Quotation (RFQ) on a Full and Open competitive basis. This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5- Simplified Procedures for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is NOT expected to exceed the simplified acquisition threshold (SAT) of $250,000.00. A Fixed-Price type of Purchase Order contract is contemplated for any resulting contract entered into as a result of this solicitation. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC Number/Effective Date: 2005-99-1 / 07-16-2018 (iv) The North American Industry Classification System (NAICS) code for this procurement is 325998 - All Other Miscellaneous Chemical Product and Preparation Manufacturing with associated small business size standard of 500 employees. (v) Background The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people's health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a part of the National Institutes of Health (NIH), whose mission it is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. NCATS was officially established in fiscal year 2012 to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. NCATS, one of 27 Institutes and Centers (ICs) at NIH, strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline in an effort to speed the delivery of new drugs, diagnostics and medical devices to patients. The NCATS Chemical Genomics Center (NCGC) seeks two (2) Chemical Libraries totaling an anticipated quantity of at least 35-40,000 specific compounds with the anticipated quantity derived from the customer's knowledge of the number of compounds that are generally known to the scientific community to be GPCR ligands/modulators. NCGC is tasked with identifying and developing novel small molecule leads against a wide spectrum of human disease targets, which it accomplishes by screening thousands of small molecules in collaboration with both intra-and extramural researchers. In pursuit of this goal, the Center has a strong internal transdisciplinary team of scientists who continually discover novel small molecules and develop novel disease models for application against a wide range of human diseases. Adding diversity to chemical libraries is imperative to NCGC to screen a variety of targets against these in-house collections. Having such small molecules will make a huge impact in screening against the variety of targets utilized by NCATS. Also, given the outsized role that GPCRs and receptor-mediated signaling pathways have in the pain/addiction fields, these libraries will also help NCGC address an upcoming anticipated influx of collaborative projects in these scientific areas. These well-curated and focused chemical libraries will help serve as important toolsets for pain/addiction and other projects, and will be ideal first-pass library choices for these collaborations, in terms of assay validation, control molecule identification and preliminary screening. Purpose and Objective: The purpose of this requirement is to obtain two (2) chemical libraries of compounds that are generally known to the scientific community to be GPCR ligands/modulators. NCATS is in need of two GPCR-focused small molecule libraries - covering both general (anticipated minimum 25,000 compounds) and allosteric (anticipated minimum 10,000 compounds) mechanisms - to be added to NCGC's panel of screening libraries. Once integrated onto NCATS's panel of screening libraries, the GPCR-focused collections will enable access to tens of thousands of opioid/pain-relevant GPCR-related molecules, and provide an important first-pass library choice for anticipated opioid-related collaborative projects. The biologically-relevant focus of these libraries, along with the novel chemical space represented therein, will allow NCATS facilities to proceed with their mission while providing focus on pain/addiction-related projects with specific technological requirements, as compared to the current screening libraries, which lack this specific pain-implicated focus. Product Description: The Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to achieve the Salient Characteristics of this requirement specified in the following: 1.Small molecule libraries comprised of GPCR ligands/modulators generally known to the scientific community representing both competitive and allosteric mechanisms, as well as pharmacophore-derived potential modulators, across a sufficient variety of receptor classes/families 2.Compounds at 2mg/powder or 400ul/10mM DMSO solution each, packaged in NCATS-supplied Matrix tubes at 88 compounds per plate 3.Small molecules guaranteed to have a purity of >90% (accuracy +/-5%) that is to be confirmed by NMR and/or LCMS spectra Contractors shall possess the technical capability to achieve the salient government essential features of this requirement and document evidence of being able to provide the subject requirement and delivery of results that will allow for the Salient Characteristics described herein to be achieved. Period of Performance/Delivery: Vendor shall deliver compounds and results within approximately 4-6 weeks after receipt of tubes from NCATS. GOVERNMENT RESPONSIBILITIES NCATS will provide 2mg barcoded tubes. DELIVERY OR DELIVERABLES Vendor shall provide the following deliverables: 1. Electronic information, in addition to the molecules themselves, for each required molecule: chemical structure or simplified molecular-input line-entry system (SMILES) or equivalent chemical structure information, supplier ID, plate ID, well location, tube ID, concentration in millimolar, and volume in microliters. This information shall be provided via email referencing individual compound vial barcodes; 2. Delivery of small molecules in the Government-provided vials to NCATS, located at 9800 Medical Center Drive, Rockville, MD 20850, to include shipping and handling. Samples will be delivered as 2mg in barcoded tubes provided by NCATS. Confidentiality of Information: All data is the property of NCATS unless otherwise specified. Inspection and Acceptance Offerors should indicate an estimated delivery time in full after receipt of an order. Inspection and acceptance will be performed at NCATS, located at 9800 Medical Center Drive, Rockville, MD 20850. (vi) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. The following is provided as an addendum to FAR clause 52.212-1, Instructions to Offerors: Offerors should indicate an estimated delivery time in full after receipt of material to be tested. (vii) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. The following is an addendum to 52.212-2: Responses received to this RFQ will be evaluated on the basis of Lowest Price Technically Acceptable (LPTA). Offeror's submitting a response must provide a completed Price Quote to be evaluated and considered for award. Price quotes must include FIXED-PRICES per unit and total fixed cost, including shipping cost and estimated time of delivery after receipt of order, and warranty and training considerations. Responses will be evaluated based on contractor's ability to meet the government's required SALIENT CHARACTERISTICS stated in this notice and on ability to deliver required supplies. Responses to this solicitation must include clear and convincing evidence of the Offeror's capability of fulfilling the requirement as it relates to the essential government requirements stated in this solicitation. Under the lowest-price technically acceptable (LPTA) process, Offerors' will be determined to be "technically acceptable" or "technically unacceptable" based on an evaluation of responses against the following factor to determine if, as submitted, the proposal is technically acceptable. (1) Technical Capability: Offerors shall clearly indicate possessing the capability to achieve the essential salient characteristic features of this requirement. The Offeror must indicate in its quotation the ability to provide all of the requirements. The Offeror must indicate in its quotation the ability to meet the delivery requirements. Offerors submitting a response with documented technical specifications and evidence of possessing the technical knowledge, qualifications and capability and management structure needed in successfully achieving the SALIENT CHARACTERISTICS identified in this requirement will be determined to be technically acceptable. Offeror's submitting a response must provide a completed Price Quote to be evaluated and considered for award. Price quotes must indicate fixed unit pricing and total cost, including shipping cost and estimated time of delivery after receipt of order. (viii) The provision at FAR Clause 52.212-3, Offeror Representations and Certifications Commercial Items, applies to this acquisition. (ix) The provision at FAR Clause 52.212-4, Contract Terms and Conditions-Commercial Items, applies to this acquisition. An addendum to FAR Clause 52.212-4, Contract Terms and Conditions-Commercial Items, Offeror Representations and Certifications Commercial Items, applies to this acquisition. (x) The provision of FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items applies to this acquisition. See attached document for applicable clauses. (xi) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiii) Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The PRICE QUOTE shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Responses to this solicitation must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria and a price proposal. Offerors must include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications Commercial Items, with their offer, or provide a copy of the valid certifications registrations and Representation and Certifications from the System of Award Management (SAM) applications at www.SAM.gov, which may be indicated on the Offeror's cover sheet. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All Offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received no later than the date specified in this announcement. Late responses will not be accepted. All responses must reference the solicitation number NIHDA201800457. Responses must be submitted electronically to hunter.tjugum@nih.gov. Facsimile responses will not be accepted. For information regarding this solicitation, contact Mr. Hunter Tjugum by email at hunter.tjugum@nih.gov or by phone at 301-827-5304.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/NIHDA201800457/listing.html)
- Record
- SN05051413-W 20180824/180822231517-71200f11f3f818c08088c8fe08676fa6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |